Maravai LifeSciences Announces Appointment of New Director to the Board
2023年7月21日 - 5:05AM
Maravai LifeSciences Holdings, Inc. (“Maravai” or the “Company”)
(NASDAQ: MRVI), a global provider of life science reagents and
services to researchers and biotech innovators, announced that
Robert (“Chip”) Hance has stepped down from the Company’s Board of
Directors (the “Board”) effective July 19, 2023, and that Dr. John
DeFord has been appointed to the Board effective July 20, 2023.
Mr. Hance, a 25-year veteran in the medical device industry, is
set to become the Chairman of the Board of the Medical Device
Innovation Consortium (MDIC) and stepped down from the Board in
anticipation of the increased time commitment associated with that
role. Dr. DeFord, a medical technology expert, was appointed to
fill the vacancy.
Dr. DeFord is the Chairman, Chief Executive Officer and
President of privately-held, South Carolina-based Samothrace
Medical Innovations, Inc., which he co-founded in March
2022. Until his retirement in May 2021, Dr. DeFord was the
Executive Vice President and Chief Technology Officer of Becton,
Dickinson and Company, a global medical technology company, which
he joined in December 2017 in connection with its acquisition of
C.R. Bard, Inc. (Bard), where he served as Senior Vice President,
science, technology and clinical affairs since June 2007. Dr.
DeFord joined Bard in 2004 and served in science and technology
roles of increasing responsibility during that time. Prior to
joining Bard, Dr. DeFord was Managing Director of Early Stage
Partners, a venture capital fund. Before Early Stage Partners, Dr.
DeFord was President and Chief Executive Officer of Cook Group,
Inc., a privately held medical device manufacturer. He also serves
on the Board of Directors of two public corporations, Nordson
Corporation, NuVasive, Inc., and also serves on the Board of
Directors of privately held Enable Injections, Inc., Blue Spark
Technologies, Inc. and GeniPhys, Inc. DeFord graduated from
Purdue University with a Bachelor’s degree and Master’s degree in
electrical engineering and a Ph.D. in electrical and biomedical
engineering.
"On behalf of the entire Board, I thank Chip for his valuable
perspective and incredible commitment to Maravai over the past six
years,” said Carl Hull, Interim Chief Executive Officer and
Chairman of the Board. “His numerous contributions and thoughtful
insights have been invaluable, and we are grateful for everything
he has done for Maravai."
Hull continued, “We also want to welcome John as a new Board
member. John is an exceptional leader, and we believe his depth of
experience in the global medical technology space will enhance our
Board and help guide Maravai through its next growth phase. We look
forward to leveraging his three decades of executive experience
guiding organizations to achieve significant scale.”
Dr. Jessica Hopfield, Chair of the Nominating, Governance and
Risk Committee of Maravai’s Board, said, “Director succession
planning is an important part of Maravai’s corporate governance,
and John’s appointment is the result of a robust process led by our
Nominating, Governance and Risk Committee in which we considered an
impressive slate of candidates, and determined that John best fit
our priorities for the skills and experience needed on the Board.
As Maravai continues to evolve, we are committed to regularly
evaluating our Board's composition to ensure we have the right mix
of skills and experience to advance our goals."
About Maravai Maravai is a leading life
sciences company providing critical products to enable the
development of drug therapies, diagnostics, and novel vaccines and
to support research on human diseases. Maravai’s companies are
leaders in providing products and services in the fields of nucleic
acid synthesis and biologics safety testing to many of the world's
leading biopharmaceutical, vaccine, diagnostics and cell and gene
therapies companies.
Forward-looking Statements This press release
may contain "forward-looking statements" within the meaning of the
safe harbor provisions of the U.S. Private Securities Litigation
Reform Act of 1995. Investors are cautioned that statements in this
press release which are not strictly historical statements
constitute forward-looking statements, including, without
limitation, statements related to the expectation that Dr. DeFord
will help guide Maravai’s growth strategy, constitute
forward-looking statements identified by words like “plan,” “will,”
“expect,” “may,” “anticipate,” or “could” and similar expressions.
Such forward-looking statements are subject to a number of risks
and uncertainties that could cause actual results to differ
materially from those anticipated, including, without limitation,
continued demand for our COVID-19 related products and services,
which currently comprise a significant portion of our revenue, and
the other risks and uncertainties described in greater detail in
the “Risk Factors” section of our most recent Annual Report on Form
10-K and other filings with the U.S. Securities and Exchange
Commission. Actual results may differ materially from those
contemplated by these forward-looking statements, and therefore you
should not rely upon them. These forward-looking statements reflect
our current views and we do not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date hereof except as
required by law.
Contact Information:
Investor Contact: Deb Hart
Maravai LifeSciences
+ 1 858-988-5917
Media Contact: Sara Michelmore
MacDougall Advisors
+1 781-235-3060
maravai@macdougall.bio
Maravai LifeSciences (NASDAQ:MRVI)
過去 株価チャート
から 4 2024 まで 5 2024
Maravai LifeSciences (NASDAQ:MRVI)
過去 株価チャート
から 5 2023 まで 5 2024